Physician profile
Bryan Thomas Mathews
NPI 1114506755
$912.43
in general payments reported to CMS, 2019-2025
19 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $196 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $154.79 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $150.74 | 2025 | Rexulti |
| Novo Nordisk INC | $103.75 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $86.42 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Biosense Webster, INC. | $76.74 | 2024 | Carto 3 |
| Lundbeck LLC | $53.01 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.13 | 2025 | Caplyta |
| Exact Sciences Corporation | $34.57 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $34.10 | 2025 | Nexletol |
| Ardelyx, INC. | $23.96 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $21.37 | 2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $20.99 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $20.87 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.32 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $17.97 | 2025 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.58 | 2024 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.70 | 2024 | Xifaxan |
| Pfizer INC. | $13.96 | 2025 | |
| Almatica Pharma LLC | $13.46 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.